<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04484090</url>
  </required_header>
  <id_info>
    <org_study_id>OHH-FE-0.1</org_study_id>
    <nct_id>NCT04484090</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Ohhmed Treatments for the Improvement of Erectile Dysfunction - A Feasibility Study</brief_title>
  <official_title>Safety and Efficacy of Ohhmed Treatments for the Improvement of Erectile Dysfunction - A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHH-MED Medical Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OHH-MED Medical Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Erectile dysfunction, the persistent inability to achieve or maintain an erection sufficient&#xD;
      for satisfactory sexual performance, is estimated to affect up to 30 million men in the&#xD;
      United States. The disorder is age-associated. The available treatments include oral therapy,&#xD;
      vacuum-constriction devices; shockwave therapy, intracavernosal injections of vasoactive&#xD;
      agents, including alprostadil (prostaglandin E1, transurethral delivery of alprostadil,&#xD;
      Implantation of penile prostheses.&#xD;
&#xD;
      The OhhMed Company has developed the Vertica device that provides treatments for improvement&#xD;
      of erectile function in patients with erectile dysfunction. This study assess the safety,&#xD;
      efficacy, ease of use, and satisfaction of the Vertica device by men with mild to moderate&#xD;
      erectile dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in erectile function (EF)</measure>
    <time_frame>Baseline to 1 month post intervention</time_frame>
    <description>The International Index for Erectile Function (IIEF) questionnaire will be administered. This is a 15 item tool; 6 ask questions addressing Erectile function over the previous 4 weeks. Scores from 0-30 can be obtained in this domain. Scores are interpreted as follows: 0-6 = Severe dysfunction, 7-12 = Moderate dysfunction, 13-18 = mild-moderate dysfunction, 19-24 = mild dysfunction, 25-30 = No dysfunction</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Vertica</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Vertica RF device for improving erectile function for men with erectile dysfunction</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vertica RF device</intervention_name>
    <description>The treatment provided by the Vertica device is indicated for improving the erectile function in men with erectile dysfunction</description>
    <arm_group_label>Vertica</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  IIEF-EF score of 11-24 with or without the use of medication (PDE5 inhibitors).&#xD;
&#xD;
          -  Erectile dysfunction for at least 3- months&#xD;
&#xD;
          -  Steady relationship for at least 3-months.&#xD;
&#xD;
          -  patient without sensory disorders&#xD;
&#xD;
          -  patient with established organic of erectile dysfunction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  investigator's impression of expected poor patient compliance or anatomic inadequacy&#xD;
             (penile size/girth)&#xD;
&#xD;
          -  Premature ejaculation&#xD;
&#xD;
          -  Any psychiatric disorder&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Peyronie 's disease/ penile curvature&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Any tumor in the pelvic or penile region within the last 3 years&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The OhhMed device provide treatments for improvement of erectile dysfunction</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilan Gruenwald, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Medical Center, Haifa Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanna Levy, PhD</last_name>
    <phone>9725228249</phone>
    <email>hanna@qsitemed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam Medical center</name>
      <address>
        <city>Haifa</city>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Levy, PhD</last_name>
      <phone>9725228249</phone>
      <email>hanna@qsitemed.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 21, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

